Cancer generics market Size, Share, Growth and Analysis Report 2022 radiant insights,

Cancer Generics Market is Anticipated to Witness a Double Digit Growth During 2022: Radiant Insights, Inc

“This number is forecasted to increase to a value of 19.3 Million by 2025. Furthermore, the patent expiry of blockbuster cancer drugs is another major factor which is propelling the growth of the cancer generics industry.�

Within the pharmaceutical industry, the oncology market is growing at a rapid pace owing to the rising incidences of cancer. In 2015, 15.2 Million new cancer cases were registered across the globe. This number is forecasted to increase to a value of 19.3 Million by 2025. Furthermore, the patent expiry of blockbuster cancer drugs is another major factor which is propelling the growth of the cancer generics industry.

"Global Cancer Generics Market Forecast to 2022", the global cancer generics market is anticipated to witness a double digit growth during 2016-2022. This report provides a detailed analysis of the current and future market scenario of the global cancer generics market. The report provides insight about the major drivers and challenges, along with the latest trends and developments impacting the industry growth. In addition, the report also highlights various opportunities available for growth of the global cancer generics market.

Read Complete Report with TOC @ http://www.radiantinsights.com/research/globalcancer-generics-market-forecast-to-2022

Follow Us:

The global cancer generics market has been segmented on the basis of mode of administration into oral and injectables. Injectables are the most widely used type of cancer generics drugs. The report also highlights the major cancer generic drugs available in the global market.

Furthermore, the global cancer generics market has also been segmented on the basis of the major indications they are used for. According to the report, breast cancer is expected to account for the largest share in 2016 due to presence of large number of generic drugs and rising incidences of this indication.

Based on geography, the report divides market into North America, Europe, and Asia-Pacific. In 2016, North America is estimated to account for the largest share. Moreover, the report also lists down various mergers and acquisitions taking place in the global generics industry.

The last section of the report discusses about the prominent players in global cancer generics market. A brief business overview and financial information about each of these players has been provided, along with their product portfolios. The recent development of every player has also been presented in the report. Overall, the research contains exhaustive information that will help clients in formulating market strategies and assessing opportunity areas in the global cancer generics market.

Read Sample report of this Category: http://www.radiantinsights.com/catalog/healthcare Table of Contents 1. Analyst View 2. Research Methodology 3. Global Cancer Drugs Market Outlook 2022 3.1 Cancer Incidences 3.2 Cancer Drug Market 4. Market Drivers & Challenges 4.1 Drivers 4.1.1 Increasing Cancer Incidences 4.1.2 Strategic Collaborations 4.1.3 Growing Geriatric Population 4.1.4 Ability to Curb Healthcare Cost 4.2 Challenges

Follow Us:

4.2.1 Growing Backlog of Generic Drug Applications 4.2.2 Counterfeit Generic Drugs 4.3 Opportunities 4.3.1 Patent Expiry of Blockbuster Oncology Drugs 4.3.2 Generic Cancer Drugs Made More Accessible to Developing Countries 5. Global Cancer Generics Market Analysis 2022 6. Global Cancer Generics Market by Mode of Administration 6.1 Oral Generics 6.1.1 Arimidex (Anastrozole) 6.1.2 Femara (Letrozole) 6.1.3 Hycamtin (Topotecan) 6.1.4 Stivarga (Regorafenib) 6.1.5 Tarceva (Erlotinib) Download sample Copy of This Report at: http://www.radiantinsights.com/research/global-cancer-generics-market-forecast-to2022/request-sample 6.1.6 Xalkori (Crizotinib) 6.1.7 Xeloda (Capecitabine) 6.1.8 Gleevec/Glivec (Imatinib Mesylate) 6.1.9 Nolvadex (Tamoxifen Citrate) 6.1.10 Targretin (Bexarotene) 6.2 Injectables Generics 6.2.1 Camptosar (Irinotecan Hydrochloride) 6.2.2 Eloxatin (Oxaliplatin) 6.2.3 Gemzar (Gemcitabine Hydrochloride) 6.2.4 Navelbine (Vinorelbine Tartrate)

Follow Us:

6.2.5 Platinol (Cisplatin) 6.2.6 Taxol (Paclitaxel) 6.2.7 Taxotere (Docetaxel) 6.2.8 Fusilev (Levoleucovorin) 6.2.9 Ellence (Epirubicin Hydrochloride) 6.2.10 Adriamycin (Doxorubicin Hydrochloride) 7. Global Cancer Generics Market by Major Indications 7.1 Lung Cancer 7.2 Breast Cancer 7.3 Colorectal Cancer 7.4 Stomach Cancer 7.5 Prostate Cancer Read Complete Report with TOC @ http://www.radiantinsights.com/research/globalcancer-generics-market-forecast-to-2022 8. Global Cancer Generics Market by Geographic Regions 8.1 US 8.2 Europe 8.3 Asia-Pacific 9. Trends & Developments 9.1 Generic Version of Blockbuster Cancer Drug 9.2 Entry of Indian Generic Cancer Drug in US 10. Mergers & Acquisitions 11. Key Players 11.1 Fresenius Kabi AG 11.2 Pfizer Inc 11.3 Teva Pharmaceutical Industries Ltd

Follow Us:

11.4 Mylan N.V 11.5 Sun Pharmaceutical Industries Ltd 11.6 Sandoz International GmbH - A Novartis Company 11.7 Sanofi 11.8 Dr. Reddy's Laboratories Ltd 11.9 Cipla Ltd 11.10 Apotex Inc

List of Tables: Table 3-1: Most Prevalent Types of Cancer, 2015 Table 4-1: Global - Key Cancer Drugs and Patent Expiry Status Table 6-1: List of Companies Dealing in Generic Arimidex Table 6-2: Cost Comparison of Generics and Branded Arimidex (Anastrozole) Table 6-3: List of Companies Dealing in Generic Femara Table 6-4: Cost Comparison of Generics and Branded Femara (Letrozole) Table 6-5: List of Companies Dealing in Generic Hycamtin Table 6-6: List of Companies Dealing in Generic Xeloda Table 6-7: Cost Comparison of Generics and Branded Xeloda (Capecitabine) Table 6-8: List of Companies Dealing in Generic Gleevec Table 6-9: Cost Comparison of Generics and Branded Gleevec (Imatinib Mesylate) Table 6-10: List of Companies Dealing in Generic Nolvadex Table 6-11: Cost Comparison of Generics and Branded Nolvadex (Tamoxifen Citrate) Table 6-12: List of Companies Dealing in Generic Targretin Table 6-13: List of Companies Dealing in Generic Camptosar Table 6-14: Cost Comparison of Generics and Branded Camptosar (Irinotecan Hydrochloride) Table 6-15: List of Companies Dealing in Generic Gemzar (Gemcitabine Hydrochloride)

Follow Us:

About Radiant Insights, Inc: Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.

Contact Details: Michelle Thoras Corporate Sales Specialist, USA Radiant Insights, Inc 28 2nd Street, Suite 3036, San Francisco, CA 94105, United States Phone: 1-415-349-0054 Toll Free: 1-888-202-9519 Email: sales@radiantinsights.com Web: http://www.radiantinsights.com/ Visit Our Blog: http://www.radiantinsightsinc.blogspot.com

Follow Us: